{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:43:08Z","timestamp":1782481388535,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum\u2010containing regimens in children with hepatoblastoma (HB).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were enrolled on P9645 beginning in March of 1999. Patients who had stage I\/II disease received treatment with 4 cycles of combined cisplatin, 5\u2010fluorouracil, and vincristine (C5V) with or without amifostine. Patients who had stage III\/IV disease were randomized to receive treatment with 6 cycles of either C5V with or without amifostine or carboplatin alternating with cisplatin (CC) with or without amifostine. Patients who were randomized to receive amifostine were given a dose of 740 mg\/m<jats:sup>2<\/jats:sup> intravenously over 15 minutes before each administration of a platinum agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Eighty\u2010two patients were considered in a special interim analysis of the incidence of toxicity. The disease outcome for patients who received amifostine was similar to the outcome for patients who did not receive amifostine (<jats:italic>P<\/jats:italic> = .22). The incidence of significant hearing loss (&gt;40 dB) was similar for patients who did or did not receive amifostine (38% [14 of 37 patients] vs 38% [17 of 45 patients], respectively; <jats:italic>P<\/jats:italic> = .68). There were no differences in the incidence of renal or bone marrow toxicities evaluated. Patients who received amifostine had a higher incidence of hypocalcemia (5% vs 0.5%; <jats:italic>P<\/jats:italic> = .00006).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum\u2010induced toxicities in patients with HB. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24667","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T16:49:55Z","timestamp":1254934195000},"page":"5828-5835","source":"Crossref","is-referenced-by-count":85,"title":["Amifostine does not prevent platinum\u2010induced hearing loss associated with the treatment of children with hepatoblastoma"],"prefix":"10.1002","volume":"115","author":[{"given":"Howard M.","family":"Katzenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay W.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton J.","family":"Finegold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleta","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B.","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Malogolowkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.96"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.12.2167"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.1050"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.400"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010201)36:2<332::AID-MPO1078>3.0.CO;2-G"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1511"},{"key":"e_1_2_7_9_2","first-page":"799","article-title":"Intensive versus standard platinum therapy for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645","volume":"23","author":"Malogolowkin M","year":"2004","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21218"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.009"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190415"},{"key":"e_1_2_7_13_2","volume-title":"Discrete Multivariate Analysis","author":"Bishop YMM","year":"1975"},{"key":"e_1_2_7_14_2","volume-title":"Statistical Methods in Medical Research","author":"Armitage P","year":"1998"},{"key":"e_1_2_7_15_2","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch J","year":"1980"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6013"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.11.014"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2101"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20132"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200203000-00006"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3974"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24667","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:38:30Z","timestamp":1760297910000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24667"}},"subtitle":["A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group"],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":20,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2009,12,15]]}},"alternative-id":["10.1002\/cncr.24667"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24667","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}